Our analyses indicate that asymptomatic patients show a trend for a less severe metastatic disease in the brain and for a better outcome (statistically significant for a cohort of HER2-positive patients) despite a less intense local BM therapy compared to symptomatic patients. The gene discussed is ERBB2; the disease is metastatic neoplasm.